A public private partnership
Strategic Vaccines LLC is a public private partnership to test and deploy FLOVID-20, an inhaled treatment for COVID-19 designed to keep COVID positive patients out of the hospital.
About Strategic Vaccines
A solution after diagnosis
Targeted immunotherapy is a medical breakthough that can offer doctors a solution after receiving a positive test for SARS COVID-2.
Watch the video below to learn more about the gap in options between vaccination and treatment.
Currently Manufacturing in Solon, Ohio
Our goal is to prevent those infected with SARS COVID-2 from progressing to the serious consequences of COVID-19. Our vaccine is currently being manufactured at Oakwood Laboratories, and we’re looking into clinical studies in Cleveland.
Tested at the Galveston National Laboratory, we were able to prevent pneumonia in infected primates by first giving them the vaccine by inhalation.
Watch the video below to see how we’ll use T-Cell Vaccine to deliver FLOVID-20 as a treatment post-diagnosis.
The T-Cell Vaccine in detail
The T-Cell vaccine delivery platform offers a unique solution in identifying and destroying infected cells, and may be used after the patient has been infected.
Watch the video below to learn more about how the T-Cell vaccine delivery platform works.
The COVID-19 Diagnosis and Treatment Path
Priority funding is going into developing a vaccine that can be distributed to an uninfected subject.
Opportunity for FLOVID-20
Currently, there are no options for a patient that has been diagnosed, but is still healthy and doesn’t require hospitalization.
Hospitalization and Therapy
Priority funding is going into developing therapies once the patient is in urgent care.